These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 21123950)

  • 1. Wt1 ablation and Igf2 upregulation in mice result in Wilms tumors with elevated ERK1/2 phosphorylation.
    Hu Q; Gao F; Tian W; Ruteshouser EC; Wang Y; Lazar A; Stewart J; Strong LC; Behringer RR; Huff V
    J Clin Invest; 2011 Jan; 121(1):174-83. PubMed ID: 21123950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased expression of the insulin-like growth factor-II gene in Wilms' tumor is not dependent on loss of genomic imprinting or loss of heterozygosity.
    Wang WH; Duan JX; Vu TH; Hoffman AR
    J Biol Chem; 1996 Nov; 271(44):27863-70. PubMed ID: 8910385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephron Progenitor But Not Stromal Progenitor Cells Give Rise to Wilms Tumors in Mouse Models with β-Catenin Activation or Wt1 Ablation and Igf2 Upregulation.
    Huang L; Mokkapati S; Hu Q; Ruteshouser EC; Hicks MJ; Huff V
    Neoplasia; 2016 Feb; 18(2):71-81. PubMed ID: 26936393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like growth factor II and WT1 transcript localization in human fetal kidney and Wilms' tumor.
    Yun K; Fidler AE; Eccles MR; Reeve AE
    Cancer Res; 1993 Nov; 53(21):5166-71. PubMed ID: 8221652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes.
    Fukuzawa R; Anaka MR; Heathcott RW; McNoe LA; Morison IM; Perlman EJ; Reeve AE
    J Pathol; 2008 Aug; 215(4):377-87. PubMed ID: 18484682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study.
    Gadd S; Huff V; Huang CC; Ruteshouser EC; Dome JS; Grundy PE; Breslow N; Jennings L; Green DM; Beckwith JB; Perlman EJ
    Neoplasia; 2012 Aug; 14(8):742-56. PubMed ID: 22952427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rodent model for Wilms tumors: embryonal kidney neoplasms induced by N-nitroso-N'-methylurea.
    Sharma PM; Bowman M; Yu BF; Sukumar S
    Proc Natl Acad Sci U S A; 1994 Oct; 91(21):9931-5. PubMed ID: 7937920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different incidences of epigenetic but not genetic abnormalities between Wilms tumors in Japanese and Caucasian children.
    Haruta M; Arai Y; Watanabe N; Fujiwara Y; Honda S; Ohshima J; Kasai F; Nakadate H; Horie H; Okita H; Hata J; Fukuzawa M; Kaneko Y
    Cancer Sci; 2012 Jun; 103(6):1129-35. PubMed ID: 22409817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular and epidemiologic characterization of Wilms tumor from Baghdad, Iraq.
    Phelps HM; Al-Jadiry MF; Corbitt NM; Pierce JM; Li B; Wei Q; Flores RR; Correa H; Uccini S; Frangoul H; Alsaadawi AR; Al-Badri SAF; Al-Darraji AF; Al-Saeed RM; Al-Hadad SA; Lovvorn Iii HN
    World J Pediatr; 2018 Dec; 14(6):585-593. PubMed ID: 30155617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-155-5p exerts tumor-suppressing functions in Wilms tumor by targeting IGF2 via the PI3K signaling pathway.
    Luo X; Dong J; He X; Shen L; Long C; Liu F; Liu X; Lin T; He D; Wei G
    Biomed Pharmacother; 2020 May; 125():109880. PubMed ID: 32004974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wilms tumor genes.
    Huff V; Saunders GF
    Biochim Biophys Acta; 1993 Dec; 1155(3):295-306. PubMed ID: 8268188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of Wilms tumor: from WT1 and microRNA to animal models.
    Tian F; Yourek G; Shi X; Yang Y
    Biochim Biophys Acta; 2014 Aug; 1846(1):180-7. PubMed ID: 25018051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic changes encompassing the IGF2/H19 locus associated with relaxation of IGF2 imprinting and silencing of H19 in Wilms tumor.
    Taniguchi T; Sullivan MJ; Ogawa O; Reeve AE
    Proc Natl Acad Sci U S A; 1995 Mar; 92(6):2159-63. PubMed ID: 7534414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of 11q loss, trisomy 12, and possible 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor.
    Watanabe N; Nakadate H; Haruta M; Sugawara W; Sasaki F; Tsunematsu Y; Kikuta A; Fukuzawa M; Okita H; Hata J; Soejima H; Kaneko Y
    Genes Chromosomes Cancer; 2006 Jun; 45(6):592-601. PubMed ID: 16518847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor.
    Ravenel JD; Broman KW; Perlman EJ; Niemitz EL; Jayawardena TM; Bell DW; Haber DA; Uejima H; Feinberg AP
    J Natl Cancer Inst; 2001 Nov; 93(22):1698-703. PubMed ID: 11717330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.
    Royer-Pokora B; Weirich A; Schumacher V; Uschkereit C; Beier M; Leuschner I; Graf N; Autschbach F; Schneider D; von Harrach M
    Cancer; 2008 Sep; 113(5):1080-9. PubMed ID: 18618575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring therapy with MEK inhibitor U0126 in a novel Wilms tumor model in Wt1 knockout Igf2 transgenic mice using 18F-FDG PET with dual-contrast enhanced CT and MRI: early metabolic response without inhibition of tumor growth.
    Flores LG; Yeh HH; Soghomonyan S; Young D; Bankson J; Hu Q; Alauddin M; Huff V; Gelovani JG
    Mol Imaging Biol; 2013 Apr; 15(2):175-85. PubMed ID: 22875335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1.
    Drummond IA; Madden SL; Rohwer-Nutter P; Bell GI; Sukhatme VP; Rauscher FJ
    Science; 1992 Jul; 257(5070):674-8. PubMed ID: 1323141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
    Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
    Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency and timing of loss of imprinting at 11p13 and 11p15 in Wilms' tumor development.
    Brown KW; Power F; Moore B; Charles AK; Malik KT
    Mol Cancer Res; 2008 Jul; 6(7):1114-23. PubMed ID: 18644976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.